Pharmaceutical composition comprising anti-GRP78 antibody as active ingredient
An object of the present invention is to provide novel pharmaceutical compositions using anti-GRP78 antibodies. More particularly, the present invention provides a novel method of cancer treatment using anti-GRP78 antibodies, novel cell growth inhibitors and anticancer agents that contain anti-GRP78 antibodies, as well as novel anti-GRP78 antibodies. The present inventor prepared antitumor antibodies to target GRP78, the localization of which in cancer cells changed to the cell membrane. The inventor successfully obtained an anti-GRP78 antibody that would bind specifically to the cell surface of cancer cells, leading to the accomplishment of the above-mentioned objects.
1. A pharmaceutical composition containing an antibody that binds to a glucose-regulated protein 78 (GRP78), wherein the antibody binds to the epitope depicted in SEQ ID NO: 3.
2. The composition according to claim 1 which is an anticancer agent.
3. The composition according to claim 1 , wherein the antibody is a monoclonal antibody.
4. The composition according to claim 1 , wherein the antibody is internalized into cells expressing GRP78.
5. The composition according to claim 1 , wherein the antibody is conjugated with a cytotoxic substance.
6. A monoclonal antibody that binds to GRP78, wherein the antibody binds to the epitope depicted in SEQ ID NO: 3.
7. The antibody according to claim 6 which is internalized into cells expressing GRP78.
8. The antibody according to claim 6 which recognizes the same epitope as the one that is recognized by an antibody selected from among the following (a) to (f):
(a) an antibody comprising a heavy-chain variable region and a light-chain variable region, the heavy-chain variable region having the amino acid sequence depicted in SEQ ID NO: 8 as CDR1, the amino acid sequence depicted in SEQ ID NO: 9 as CDR2, and the amino acid sequence depicted in SEQ ID NO: 10 as CDR3, and the light-chain variable region having the amino acid sequence depicted in SEQ ID NO: 11 as CDR1, the amino acid sequence depicted in SEQ ID NO: 12 as CDR2, and the amino acid sequence depicted in SEQ ID NO: 13 as CDR3;
(b) an antibody comprising a heavy-chain variable region and a light-chain variable region, the heavy-chain variable region having the amino acid sequence depicted in SEQ ID NO: 18 as CDR1, the amino acid sequence depicted in SEQ ID NO: 19 as CDR2, and the amino acid sequence depicted in SEQ ID NO: 20 as CDR3, and the light-chain variable region having the amino acid sequence depicted in SEQ ID NO: 21 as CDR1, the amino acid sequence depicted in SEQ ID NO: 22 as CDR2, and the amino acid sequence depicted in SEQ ID NO: 23 as CDR3;
(c) an antibody comprising a heavy-chain variable region and a light-chain variable region, the heavy-chain variable region having the amino acid sequence depicted in SEQ ID NO: 61 as CDR1, the amino acid sequence depicted in SEQ ID NO: 62 as CDR2, and the amino acid sequence depicted in SEQ ID NO: 63 as CDR3, and the light-chain variable region having the amino acid sequence depicted in SEQ ID NO: 64 as CDR1, the amino acid sequence depicted in SEQ ID NO: 65 as CDR2, and the amino acid sequence depicted in SEQ ID NO: 66 as CDR3;
(d) an antibody comprising a heavy-chain variable region and a light-chain variable region, the heavy-chain variable region having the amino acid sequence depicted in SEQ ID NO: 71 as CDR1, the amino acid sequence depicted in SEQ ID NO: 72 as CDR2, and the amino acid sequence depicted in SEQ ID NO: 73 as CDR3, and the light-chain variable region having the amino acid sequence depicted in SEQ ID NO: 74 as CDR1, the amino acid sequence depicted in SEQ ID NO: 75 as CDR2, and the amino acid sequence depicted in SEQ ID NO: 76 as CDR3;
(e) an antibody comprising a heavy-chain variable region and a light-chain variable region, the heavy-chain variable region having the amino acid sequence depicted in SEQ ID NO: 81 as CDR1, the amino acid sequence depicted in SEQ ID NO: 82 as CDR2, and the amino acid sequence depicted in SEQ ID NO: 83 as CDR3, and the light-chain variable region having the amino acid sequence depicted in SEQ ID NO: 84 as CDR1, the amino acid sequence depicted in SEQ ID NO: 85 as CDR2, and the amino acid sequence depicted in SEQ ID NO: 86 as CDR3; and
(f) an antibody comprising a heavy-chain variable region and a light-chain variable region, the heavy-chain variable region having the amino acid sequence depicted in SEQ ID NO: 91 as CDR1, the amino acid sequence depicted in SEQ ID NO: 92 as CDR2, and the amino acid sequence depicted in SEQ ID NO: 93 as CDR3, and the light-chain variable region having the amino acid sequence depicted in SEQ ID NO: 94 as CDR1, the amino acid sequence depicted in SEQ ID NO: 95 as CDR2, and the amino acid sequence depicted in SEQ ID NO: 96 as CDR3.
9. The antibody according to claim 6 which has cytotoxic activity against cells expressing GRP78.
10. The antibody according to claim 9 which is conjugated with a cytotoxic substance.
11. An anti-GRP78 antibody conjugated with a labeling substance, where the antibody binds to the epitome depicted in SEQ ID NO: 3.
12. A method of delivering a cytotoxic substance into cells using an anti-GRP78 antibody comprising contacting cells with the anti-GRP78 antibody of claim 5 .
13. A method of suppressing the growth of cells using a cytotoxic substance bound to an anti-GRP78 antibody comprising contacting cells with the cytotoxic substance bound to the anti-GRP78 antibody of claim 6 .
14. The method according to claim 12 or 13 , wherein the cells are cancer cells.
15. The method according to claim 14 , wherein the cancer cells are selected from the group consisting of prostate cancer cells, breast cancer cells, colon cancer cells, and ovary cancer cells.
16. A process for producing a pharmaceutical composition comprising the following steps:
(a) the step of providing GRP78 antibodies according to claim 6 ;
(b) the step of validating whether the antibodies of (a) have an internalizing activity;
(c) the step of selecting antibodies having an internalizing activity; and
(d) the step of binding a cytotoxic substance to the antibodies selected in (c).
17. The process according to claim 16 , wherein the pharmaceutical composition is an anticancer agent.
18. A method of diagnosing a cancer expressing GRP78 using the anti-GRP78 antibody of claim 6 .
19. The method of diagnosing according to claim 18 which uses an anti-GRP antibody conjugated with a labeling substance.
20. The method of diagnosing according to claim 18 which detects the anti-GRP78 antibody incorporated into cells.